Search Result

Results for "

Mmp13 Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MMP (64) Akt (1) Angiotensin Receptor (3) AP-1 (3) Apoptosis (6) ASK1 (2) Autophagy (2) COX (2) Endogenous Metabolite (1) ERK (1) Fluorescent Dye (1) Isotope-Labeled Compounds (1) JNK (2) NF-κB (4) p38 MAPK (5) PGE synthase (1) Potassium Channel (1) Ras (1) Reference Standards (8) Ser/Thr Protease (1) SOD (2) TGF-beta/Smad (4) TGF-β Receptor (4) TNF Receptor (4) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (27) Cardiovascular Disease (17) Endocrinology (2) Inflammation/Immunology (32) Metabolic Disease (2) Neurological Disease (9)

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

GMP Molecules

Targets Recommended: MMP Serpin

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-12270

T-5224 Maximum Cited Publications 100 Publications Verification	AP-1 MMP	Neurological Disease Inflammation/Immunology Cancer
T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription .

HY-N1463

Luteolin 7-O-glucuronide 3 Publications Verification Luteolin 7-glucuronide	MMP	Neurological Disease Inflammation/Immunology
Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .

HY-110397

KP-457 3 Publications Verification	MMP	Cardiovascular Disease
KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC₅₀s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.

HY-100113

Buloxibutid 5 Publications Verification AT2 receptor agonist C21	Angiotensin Receptor p38 MAPK TGF-beta/Smad TGF-β Receptor MMP	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a K_i value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase *MMP-13) and tissue repair mainly by activating the NO/cGMP* pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .

HY-N1454

Apigenin-7-glucuronide 4 Publications Verification Apigenin 7-O-glucuronide	MMP	Cancer
Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-107394

UK 356618 5+ Cited Publications	MMP	Inflammation/Immunology Cancer
UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC₅₀ of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with MMP-3 .

HY-100359

CL-82198 5+ Cited Publications	MMP	Inflammation/Immunology Cancer
CL-82198 is a selective inhibitor of *MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13* and the lack of inhibitory activities against other MMPs . CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression .

HY-12875

BQU57	Ras	Cancer
BQU57 is a selective inhibitor of RalA/RalB small GTPases, with a binding potency (Kb) of 7.7 μM for RalB-GDP. BQU57 can block its interaction with effector proteins (such as SEC5 and EXO84), inhibiting tumor cell migration, invasion and non-adherent growth. BQU57 downregulates the NF-κB signaling pathway, reduces the expression of IL-6, IL-8 and *MMP-13, and inhibits* apoptosis by regulating the Bcl-2/Bax balance. BQU57 also protects the extracellular matrix by inhibiting the Ral/NF-κB pathway and can be used for the study of degenerative diseases. BQU57 exhibits significant antitumor activity in triple-negative breast cancer (TNBC) models, inhibiting orthotopic tumor growth and lung metastasis and enhancing paclitaxel chemotherapy sensitivity .

HY-12170

Prinomastat 4 Publications Verification AG3340; KB-R9896	MMP Apoptosis	Cancer
Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC₅₀s of 79, 6.3 and 5.0 nM for *MMP-1, MMP-3* and MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3, *MMP-13* and MMP-9 with K_is of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity .

HY-124029

BI-4394 Mmp13-IN-3	MMP	Inflammation/Immunology
BI-4394 (MMP13-IN-3), a chemical probe, is a potent, selective, and orally active *MMP-13* inhibitor (IC₅₀=1 nM ) for the potential treatment of osteoarthritis . BI-4394 is >1000 selective over other MMPs .

HY-100518

T-26c 3 Publications Verification	MMP	Inflammation/Immunology
T-26c, a chemical probe, is highly potent and selective matrix metalloproteinase-13 (MMP-13) inhibitor with an IC₅₀ of 6.75 pM and more than 2600-fold selectivity over the other related metalloenzymes .

HY-N2350

Cynaropicrin	MMP NF-κB TNF Receptor	Cancer
Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release with IC₅₀s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin also inhibits the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.

HY-19820A

NSC45586 sodium 1 Publications Verification	Akt Ser/Thr Protease Apoptosis MMP	Cardiovascular Disease Neurological Disease Inflammation/Immunology
NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of *MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin*), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration .

HY-125166

DB04760 1 Publications Verification	MMP	Neurological Disease Cancer
DB04760 (compound 4) is a potent, highly selective, non-zinc-chelating *MMP-13* inhibitor with an IC₅₀ of 8 nM . DB04760 significantly reduces paclitaxel neurotoxicity and has anticancer activity .

HY-19485

XL-784 2 Publications Verification	MMP	Cardiovascular Disease
XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC₅₀s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-10398

CTS-1027 4 Publications Verification Ro 1130830; RS 130830	MMP	Cancer
CTS-1027 is a potent small molecule inhibitor of MMPs, with IC₅₀s of 0.3 nM, 0.5 nM for MMP2, *MMP13, respectively, and has > 1,000 fold selectivity over MMP1*.

HY-12170A

Prinomastat hydrochloride 4 Publications Verification AG3340 hydrochloride; KB-R9896 hydrochloride	MMP Apoptosis	Cancer
Prinomastat hydrochloride (AG3340 hydrochloride) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC₅₀s of 79, 6.3 and 5.0 nM for *MMP-1, MMP-3* and MMP-9, respectively. Prinomastat hydrochloride inhibits MMP-2, MMP-3, *MMP-13* and MMP-9 with K_is of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat hydrochloride can cross blood-brain barrier. Antitumor avtivity .

HY-12093

MMP408 1 Publications Verification	MMP	Inflammation/Immunology
MMP408 is a selective and orally effective inhibitor of MMP-12 with IC₅₀ values for human, mouse and rat MMP-12 of 2 nM, 160 nM and 3 μM respectively. MMP408 exhibits IC₅₀ value for human *MMP-13* of 120 nM, and its activity against other MMPs is weak. MMP408 can alleviate inflammation, fibrosis and tissue remodeling by inhibiting MMP-12. MMP408 can be used in the research of chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps .

HY-107639

UK-370106	MMP	Inflammation/Immunology
UK-370106 is a potent and highly selective MMP-3 (IC₅₀ of 23 nM) and MMP-12 (IC₅₀ of 42 nM) inhibitor with >1200-fold higher potency than MMP-1, MMP-2, MMP-9, and MMP-14, and about 100-fold than MMP-13 and MMP-8. UK-370106 potently inhibits cleavage of [ ³H]-fibronectin by MMP-3 (IC₅₀ of 320 nM) and has little effect on keratinocyte migration in vitro .

HY-107428

PD-166793	MMP	Cardiovascular Disease
PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and *MMP-13* (IC₅₀=4, 7, and 8 nM, respectively) and micromolar potency vs *MMP-1, -7 and -9 (IC₅₀*=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure .

HY-122624

MMP13-IN-2	MMP	Inflammation/Immunology
MMP13-IN-2 is a potent, selective and orally active *MMP-13* inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC₅₀=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research .

HY-128026

MMP-9/MMP-13 Inhibitor I	MMP	Inflammation/Immunology
MMP-9/MMP-13 Inhibitor I is a potent MMP-9 and *MMP-13* inhibitor with IC₅₀s of both 0.9 nM. MMP-9/MMP-13 Inhibitor I shows >20-folds selectivity for MMP-9/MMP-13 over other MMPs .

HY-12168

Tanomastat BAY 12-9566	MMP	Cancer
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The K_i values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .

HY-N1508

Ecliptasaponin A	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of *MMP13* and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

HY-W011085

CP-471474 1 Publications Verification	MMP	Inflammation/Immunology
CP-471474 is an orally active and pan MMP inhibitor, with IC₅₀ values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively .

HY-116302

MMP-9-IN-9	MMP	Neurological Disease Inflammation/Immunology
MMP-9-IN-9 (compound 4f) is a slective MMP-9 inhibitor with an IC₅₀ of 5 nM. MMP-9-IN-9 shows selective for MMP-9 over MMP-1 and MMP-13. MMP-9-IN-9 shows strong anti-inflammatory and neuroprotective effects .

HY-147745

MMP2-IN-2	MMP	Cancer
MMP2-IN-2 (compound 42) is a potent and selective MMP-2 (matrix metalloproteinases) inhibitor, with an IC₅₀ of 4.2 μM. MMP2-IN-2 also shows inhibitory activity against *MMP-13, MMP-9* and MMP-8, with IC₅₀ values of 12, 23.3, and 25 μM, respectively .

HY-117970

MMPI-1154	MMP	Cardiovascular Disease
MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC₅₀=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC₅₀s of 1.8 μM,10 μM, and 13 μM, respectively .

HY-N2503

Ginsenoside F4	Apoptosis MMP	Inflammation/Immunology
Ginsenoside F4 (GF4), ginseng saponinis, isolated from notoginseng or red ginseng. Ginsenoside F4 (GF4) has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis . Ginsenoside F4 (GF4) inhibits matrix metalloproteinase 13 (MMP 13) expression in IL-1β-treated chondrocytes and blocks cartilage breakdown in rabbit cartilage tissue culture, shows therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues .

HY-114091

PF-00356231 hydrochloride 2 Publications Verification	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase MMP-12 (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively .

HY-120505

ITZ-1	ERK p38 MAPK	Inflammation/Immunology
ITZ-1 is an orally active and selective extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway inhibitor with an IC₅₀ of 0.51 μM for inhibiting interleukin-1β (IL-1β)-induced matrix metalloproteinase-13 (MMP-13) production. ITZ-1 reduces MMP-13 expression and suppresses nitric oxide (NO)-induced chondrocyte apoptosi. ITZ-1 is promising for research of osteoarticular diseases .

HY-112160

XL-784 free base	MMP	Cardiovascular Disease
XL-784 free base is a selective matrix metalloproteinases (MMP) inhibitor, with IC₅₀s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13, respectively .

HY-N1454R

Apigenin-7-glucuronide (Standard) Apigenin 7-O-glucuronide (Standard)	Reference Standards MMP	Cancer
Apigenin-7-glucuronide (Standard) is the analytical standard of Apigenin-7-glucuronide. This product is intended for research and analytical applications. Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-14237

SC-77964	MMP	Inflammation/Immunology Cancer
SC-77964 is a potent, selective and orally active matrix metalloprotease (MMP) inhibitor. SC-77964 shows IC₅₀ values < 0.1 nM against MMP-2, MMP-9, and MMP-13. SC-77964 can be used for the research of cancer and inflammation, such as melanoma .

HY-107640

WAY-170523	MMP	Cancer
WAY-170523 is a potent and selective MMP-13 (matrix metalloproteinase-13) inhibitor, with an IC₅₀ of 17 nM. WAY-170523 can directly attenuate ERK1/2 phosphorylation. WAY-170523 inhibits the invasion of PC-3 cells, can be used for prostate cancer research .

HY-N1463R

Luteolin 7-O-glucuronide (Standard) Luteolin 7-glucuronide (Standard)	Reference Standards MMP	Neurological Disease Inflammation/Immunology
Luteolin 7-O-glucuronide (Standard) is the analytical standard of Luteolin 7-O-glucuronide. This product is intended for research and analytical applications. Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .

HY-12270R

T-5224 (Standard)	AP-1 MMP	Others
T-5224 (Standard) is the analytical standard of T-5224. This product is intended for research and analytical applications. T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription .

HY-110397G

KP-457	MMP	Cardiovascular Disease
KP-457 (GMP) is KP-457 (HY-110397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture.KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC₅₀s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively .

HY-149377

MMP13-IN-4	MMP	Metabolic Disease
MMP13-IN-4 (compound 13) is a potent and selective inhibitor of *MMP-13* (IC₅₀=14.6 μM)，involved in osteoarthritis (OA) .

HY-110046

CL-82198 hydrochloride	MMP	Others
CL-82198 hydrochloride is a selective inhibitor of *MMP-13. CL-82198 hydrochloride binds to the entire S1’ pocket of MMP-13, which is the basis of its selectivity against MMP*-1, MMP-9, and TACE .

HY-154868

MMP-13-IN-1	MMP	Cardiovascular Disease Cancer
MMP-13-IN-1 is a potent and selective inhibitor of *MMP-13* with a IC₅₀ value of 16 nM. MMP-13-in-1 can be used for atherosclerosis research .

HY-107013

CP-544439	MMP	Inflammation/Immunology
CP-544439 is a potent and orally active matrix metalloproteinase-13 *(MMP-13)* inhibitor with an IC₅₀ of 0.75 nM .

HY-129699

RH01617	Potassium Channel MMP	Cardiovascular Disease
RH01617 is a Kv1.5. potassium channel and *MMP-13* inhibitor. RH01617 can be used for research of atrial fibrillation .

HY-119185

AZD-6605	Endogenous Metabolite	Cancer
AZD-6605 is a potent, reversible inhibitor of MMP2, MMP9, MMP12 and MMP13 with excellent selectivity. During drug development, AZD-6605 was optimized for activity, solubility and DMPK properties against MMP13 by replacing the zinc hydroxide binding group associated with historical inhibitors .

HY-123438

WAY-151693	MMP	Others
WAY-151693, sulfonamide derivative of a hydroxamic acid, acts as a potent inhibitor of *MMP13* in virtual screening .

HY-149378

MMP13-IN-5	MMP	Metabolic Disease
MMP13-IN-5 (compound 13m) is a potent and selective inhibitor of *MMP-2/MMP-13* (IC₅₀=3.6 μM/14.6 μM)，involved in osteoarthritis (OA) .

HY-114396

BR351	MMP	Cancer
BR351 is a brain penetrant MMP inhibitor with IC₅₀s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively .

HY-100518A

T 26c sodium	MMP	Inflammation/Immunology
T26c sodium is a potent and selective *MMP13* inhibitor with IC₅₀ value of 6.9 pM. T26c sodium can inhibit the degradation of bovine nasal septal cartilage explants .

HY-43586

BR351 precursor	MMP	Cancer
BR351 precursor is a precursor of BR351. BR351 is a brain penetrant MMP inhibitor with IC₅₀s of 4, 2, 11, 50 nM for MMP2, MMP8, MMP9 and MMP13, respectively .

HY-110116

SD-2590 hydrochloride	MMP	Cardiovascular Disease Inflammation/Immunology Cancer
SD-2590 hydrochloride is a potent MMP inhibitor with IC₅₀ values of ﹤0.1, ﹤0.1, 0.18, and 1.7 nM for MMP2, MMP13, MMP9, and MMP8, respectively. SD-2590 hydrochloride inhibits dilation of the left ventricle in rats .

Art. -Nr.	Produktname	Type

HY-110397G

KP-457

Fluorescent Dyes

KP-457 (GMP) is KP-457 (HY-110397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture.KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC₅₀s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively .

Art. -Nr.	Produktname	Type

HY-110397G

KP-457

Biochemical Assay Reagents

Art. -Nr.	Produktname	Category	Target	Chemical Structure

HY-N1463

Luteolin 7-O-glucuronide 3 Publications Verification Luteolin 7-glucuronide	Structural Classification Flavonoids other families Classification of Application Fields Flavones Other Diseases Phenols Polyphenols Plants Disease Research Fields Source Classification	MMP
Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .

HY-N1454

Apigenin-7-glucuronide 4 Publications Verification Apigenin 7-O-glucuronide	Structural Classification Flavonoids other families Classification of Application Fields Flavones Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	MMP
Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-N2350

Cynaropicrin	Saussurea costus (Falc.) Lipsch. Classification of Application Fields Phenols Plants Compositae Disease Research Fields Source Classification Cancer	MMP NF-κB TNF Receptor
Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release with IC₅₀s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin also inhibits the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.

HY-N1508

Ecliptasaponin A	Triterpenes other families Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of *MMP13* and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

HY-N2503

Ginsenoside F4	Panax ginseng C. A. Meyer Triterpenes Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Araliaceae Source Classification	Apoptosis MMP
Ginsenoside F4 (GF4), ginseng saponinis, isolated from notoginseng or red ginseng. Ginsenoside F4 (GF4) has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis . Ginsenoside F4 (GF4) inhibits matrix metalloproteinase 13 (MMP 13) expression in IL-1β-treated chondrocytes and blocks cartilage breakdown in rabbit cartilage tissue culture, shows therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues .

HY-N1454R

Apigenin-7-glucuronide (Standard) Apigenin 7-O-glucuronide (Standard)	Structural Classification Flavonoids other families Flavones Phenols Polyphenols Plants Source Classification	Reference Standards MMP
Apigenin-7-glucuronide (Standard) is the analytical standard of Apigenin-7-glucuronide. This product is intended for research and analytical applications. Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-N1463R

Luteolin 7-O-glucuronide (Standard) Luteolin 7-glucuronide (Standard)	Structural Classification Flavonoids other families Flavones Phenols Polyphenols Plants Source Classification	Reference Standards MMP
Luteolin 7-O-glucuronide (Standard) is the analytical standard of Luteolin 7-O-glucuronide. This product is intended for research and analytical applications. Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .

HY-W670700

2,5-Dihydroxy-4-methoxyacetophenone	Structural Classification Asclepiadaceae Phenols Polyphenols Cynanchum paniculatum (Bunge) Kitagawa Plants Source Classification	MMP
2,5-Dihydroxy-4-methoxyacetophenone (compounds 3) can be isolated from the 80% methanol extract of roots of Cynanchum paniculatum Kitagawa. 2,5-Dihydroxy-4-methoxyacetophenone inhibits glutamate-induced cytotoxicity in hippocampal HT22 cell line . 2,5-Dihydroxy-4-methoxyacetophenone significantly inhibites MMP-13 expression in SW1353 cells, and have the potential for alleviating cartilage degradation .

HY-N2350R

Cynaropicrin (Standard)	Saussurea costus (Falc.) Lipsch. Structural Classification Phenols Plants Compositae Source Classification	Reference Standards MMP NF-κB TNF Receptor
Cynaropicrin (Standard) is the analytical standard of Cynaropicrin. This product is intended for research and analytical applications. Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release with IC₅₀s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin also inhibits the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.

HY-N1508R

Ecliptasaponin A (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK
Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of *MMP13* and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.

Art. -Nr.	Produktname	Chemical Structure

HY-12270S

T-5224-d8
T-5224-d₈ is the deuterium labeled T-5224 (HY-12270). T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription .

Targets Recommended: MMP Serpin

Art. -Nr.	Produktname	Target	Forschungsgebiete	Chemical Structure

HY-110397G

KP-457	MMP	Cardiovascular Disease
KP-457 (GMP) is KP-457 (HY-110397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture.KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC₅₀s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively .

Online-Anfrage

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Anrede			Country or Region *
Name des Antragstellers *			Name der Organisation *
Department *
E-Mail-Addresse *			Produktname *
Art. -Nr.			Requested quantity *
Telefonnummer *
Bemerkungen

Online-Anfrage

Inquiry Information

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Mmp13 Inhibitors

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

GMP Molecules

Natural
Products